Compare Cassava Sciences Inc (FLNA) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs GE HealthCare Technologies Inc. Common Stock — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.91M), while GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 865.2× Cassava Sciences Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | GEHC | |
|---|---|---|
Market Cap | $35.91M | $31.07B |
Volume | 323,246 | 3,443,020 |
Sector | Health | Health |
52-Week High | $4.64 | $88.16 |
52-Week Low | $0.68 | $59.48 |
Typical Hold Time | 38 Days | — |
Enterprise Value | -$46.77M | $39.53B |
Dividend Yield | — | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.7316, down 4.93% today, amid bearish technical signals despite recent FDA progress. The stock shows negative profitability with ROE at -55.79% and consistent negative cash flow, though it has beaten EPS estimates for three consecutive quarters. Analyst consensus remains positive with 8 buy ratings versus 4 holds.
The outlook hinges on clinical development success, particularly the Phase 2a study for TSC-related epilepsy. Investment opportunity exists if trials progress favorably, but risks include cash burn, regulatory hurdles, and persistent losses. Current valuation metrics like EV/EBITDA of 1.11 suggest potential upside if execution improves.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
